Sanity Group

Sanity Group survey: Almost 81 percent support legalization of cannabis in various forms

April 12, 2020

Federal states in which the majority of respondents support the medical use of cannabis have a majority in the Bundesrat. 47.8 percent of women are in favor of legalizing cannabis for medical purposes, 44.5 percent of men are in favor of the complete legalization of cannabis with regulation and taxation. A majority of parents are in favor of allowing the medical use of cannabis. 

“We at the Sanity Group value open, social debate and are constantly striving to find and implement ways to improve social well-being. Thanks to its proven positive effects in many cases, we believe that cannabis has a strong potential, both medically for society and, as a consequence, for the improvement of health for the national economy. According to the European Cannabis Report (4th edition), the European cannabis industry has a potential total market value of 123 billion euros by 2028. That is why we wanted to broaden the discussion by providing reliable data and insights into the overall social perception in Germany,” says Finn Hänsel, Managing Director of the Sanity Group GmbH. 

The majority of respondents in all German states support the legalization of cannabis to a certain extent. In this context, federal states in which the majority of participants support the medical use of cannabis have a total share of more than half of the seats in the Federal Council, the distribution of which depends on the population. 

Among the male and female respondents, the results show that the majority at least advocates the medical legalization of cannabis. 35.3 percent of men support the current legal status of cannabis on medical prescription, with the larger group and almost half of the male voters (44.5 percent) support the complete legalization of cannabis with regulation and taxation. 

While the majority of women are generally against the criminalization of cannabis, their results show the opposite of male voters in terms of the extent of legality: 47.8 percent of the respondents support the legalization of cannabis for medical purposes, while 32 percent of women support the full legalization of cannabis. 

Parents are generally positive about cannabis: 38 percent of this population group supports the legalization and taxation of cannabis, which is 3.5 percent more than those who support cannabis as medicine (34.5 percent). 

Childless people speak out in favor of cannabis with a proportion of 38.2 percent favors legalization of cannabis where regulation and taxation exist, while medically prescribed cannabis is preferred with 44.1 percent. 

This survey was conducted through Civey, an external opinion polling platform with machine learning technology. For this purpose, an online survey network of more than 25,000 websites (URLs) was used by Civey Riversampling to obtain the opinion of users around the clock. Civey relies on nonprobability samples and has developed a procedure to compensate for possible distortions. The survey responses were analyzed to verify that the user is a real person, provides sufficient information and measures the possibility that his or her answer is truthful. 

A quoted sample of approximately 5,000 respondents is drawn based on variables such as age, gender, voting intention for the Bundestag election, time of voting, and place of voting to ensure that a minimum number of respondents from each population group were considered. Thus the survey is considered representative. Finally, the votes in the sample are re-weighted according to other socio-demographic aspects such as age, gender, marital status, population density, purchasing power and party preference to correct any remaining distortions. Finally, the weighting of the data is based on the official population data, which are obtained from the Federal Statistical Office or the Federal Election Commissioner. 

About Sanity Group

The Sanity Group and its subsidiaries develop innovative cannabinoid-based pharmaceuticals as well as wellness and cosmetic products and make them easily accessible throughout Europe. To exploit the full potential of their health benefits, the Sanity Group invests in basic research on the cannabis plant and its active ingredients, as well as in specific areas of application. Equipped with this knowledge, the Sanity Group’s team of experts continuously educates healthcare professionals, patients, and consumers and supports them in leading a healthier life.

Sanity Group

Sanity Group raises €20 million​

February 12, 2020

Sanity Group, one of Europe’s leading medical cannabis and wellness brands is pleased to announce the completion of a €20 million round led by Calyx, a European Cannabis-focused investment fund and HV Holtzbrinck Ventures, one of Germany’s largest Venture Funds. Among the participants are also Karan Wadhera (managing partner at Casa Verde),  Scooter Braun’s investment fund TQ Ventures and Berlin-based Cherry Ventures. This investment represents the largest cannabis financing round in Europe to date.

Sanity Group aspires to become a market leader in the fast-growing German and European cannabis markets. The company, founded in 2018 by German entrepreneurs and cannabis advocates Finn Hänsel and Fabian Friede, is fully licensed and currently operational with two business units, Sanatio Pharma, a medical cannabis company devoted to the development of new therapies and pharmaceuticals, and wellness brand VAAY.

“Sanity Group is not only investing in the wholesale of medical cannabis but also in research, internationalization, drug approval, alternative dosage forms and the use of cannabinoids for wellness products, including cosmetics,” says Managing Director Finn Hänsel. “Our aim is to become number one in Europe, a market that some believe could surpass North America in size and volume, depending on the progress of legalization across the European continent.”

The lead investors are joined in the $22M in capital raise by existing Sanity Group investors Atlantic Food Labs and several angel investors including the founders of the well-known German advertising agency HEIMAT. The funds will be used to drive forward strategic projects to give people better access to medical and medically-related cannabis products.

“Sanity Group has quickly established itself at the forefront of innovation in Germany, the fastest-growing cannabis market in Europe,” says Karan Wadhera, Managing Partner, Casa Verde Capital. “With a strong penetration into pharmacies across Germany, a multitude of THC and CBD formulations serving the medical cannabis segment, an array of well-being products already in market, and an assembled team of world-class scientific and operational experts, we believe the company is well-positioned to become a global leader in both the medical cannabis and wellness categories.”

About Sanity Group

Sanity Group is a Berlin-based holding company dedicated to the research, development and licensed distribution of cannabis-based drugs and medically related products. Subsidiaries of the Sanity Group are Sanatio Pharma GmbH (medical wholesale and research) and VAAY GmbH (wellness products).

Sanity Group

Sanity Group joins Medicinal Cannabis Europe as Executive Board Member​

January 30, 2020

On 30 January 2020, Medicinal Cannabis Europe’s first General Assembly took place, officially establishing the only European multi-stakeholder association representing the whole medicinal cannabis value chain.

Sanity Group has joined Medicinal Cannabis Europe because it comprises patients’, medical and scientific organisations, NGOs and industry representatives, with the ultimate goal of ensuring patients’ fair access to medicinal cannabis in Europe.

The therapeutic properties of medicinal cannabis applications are increasingly being acknowledged by the scientific world, however access to these medicines remains fragmented within and between European Member States. This seriously affects patients’ ability to receive the care they need, as well as the industry’s capacity to produce, process and distribute safe and high-quality medicinal cannabis products across the European Single Market. Against this background, Medicinal Cannabis Europe calls for:

1. An EU harmonised regulatory framework on medicinal cannabis;

2. The allocation of EU funds for research on medicinal cannabis;

3. The promotion of an open, societal dialogue on the benefits of medicinal cannabis.

Fabian Friede, Founder and Managing Director of Sanity Group: 

“I am honored to be joining the Executive Board of Medicinal Cannabis Europe as Treasurer. I believe Medicinal Cannabis Europe is paving the way in facilitating a long-lasting dialogue between patients, medical and scientific communities, industry and policymakers. Only by working together can we promote the health benefits of medicinal cannabis and ensure fair and safe access to patients in Europe. I am enthusiastic about contributing to this mission.”

Medicinal Cannabis Europe has already been actively advocating at European level for almost two years and indends to continue its advocacy activities, amongst others via:

• The promotion of a policy pledge, launched in 2019 seeking the support of Members of the European Parliament (MEPs) on the above-mentioned points;

• The promotion of research on medicinal cannabis via Horizon Europe, the future EU research and innovation framework programme;

• The elaboration of a European Citizen Initiative (ECI) on medicinal cannabis, whose process will be initiated in the first quarter of 2020.

Medicinal Cannabis Europe’s activities will be carried out by the Secretariat, represented by its Secretary General Stuart Lambie, under the aegis of the association’s Executive Board, chaired by Dr. Vincenzo Costigliola.